InterMune Enters New Actimmune Supply Pact

InterMune, Inc. has entered into a new supply agreement with Boehringer Ingelheim Austria GmbH for Actimmune, eliminating InterMune’s $91.6 million in future purchase commitments that existed under the previous supply agreement. InterMune will pay BI Austria approximately $5.5 million. Under the terms of the new supply agreement, InterMune is not required to make any minimum annual purchase commitments and BI Austria is not required to commit to reserving any minimum annual capacity for the manufacture of Actimmune.

Dan Welch, chief executive officer of InterMune, said, “We are very pleased to have eliminated the significant purchase commitments of the previous supply agreement and established a new supply agreement for Actimmune on terms that are attractive to InterMune. Our new supply agreement provides for a steady supply of Actimmune at the same cost as our previous supply agreement and allows flexibility to adapt supply to future demand for Actimmune.”